<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland</h1>

    <table>
      <tr><th>Ticker</th><td>OTLK</td></tr>
      <tr><th>Float</th><td>44.5 M</td></tr>
      <tr><th>IO</th><td>10.09%</td></tr>
      <tr><th>MC</th><td>34.2 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Outlook Therapeutics announced an exclusive commercial distribution agreement with Mediconsult AG to commercialize LYTENAVA™ (bevacizumab gamma) in Switzerland, described as an expansion of the company's European footprint. The provided material does not disclose financial terms or other commercial details.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA in Switzerland</li><li>Company states this expands its European commercial footprint</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>No financial or commercial terms disclosed in the provided text</li><li>Market capitalization reported as $34.2M (metadata)</li><li>Float reported as 44.5M and institutional ownership 10.09% (metadata)</li></ul>
    </div>

    <div class="section">
      <a href="https://newsfilter.io/articles/outlook-therapeutics-expands-european-footprint-with-exclusive-commercial-distribution-agreement-wit-c156919cc862a73e636ac1e6d99b7c85" target="_blank">Original Article</a>
    </div>

    <div class="small">OTLK • TradersLink AI News</div>
  </div>
</body>
</html>